Immunovant
IMVT
112 hedge funds and large institutions have $238M invested in Immunovant in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 5 closing their positions.
417% more call options, than puts
Call options by funds: $3.18M | Put options by funds: $614K
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
52% more capital invested
Capital invested by funds: $157M → $238M (+$81.3M)
19% more funds holding
Funds holding: 94 → 112 (+18)
2.15% more ownership
Funds ownership: 34.45% → 36.59% (+2.1%)
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.62M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$8.17M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.97M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.98M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.15M |
| 2 |
JP Morgan Chase
New York
|
-$2.4M |
| 3 |
Two Sigma Investments
New York
|
-$1.43M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$1.42M |
| 5 |
Two Sigma Advisers
New York
|
-$973K |
IMVT Hedge Fund Activity: Q3 2022 in Review
112 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2022, worth a combined $238M — up 52% from $157M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new IMVT positions and 5 closed out — a net gain of 18 holders — while 36 added to existing stakes and 33 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.62M. The largest seller was Federated Hermes, cutting an estimated $9.15M.
- 112 institutional investors held Immunovant (IMVT) as of Q3 2022, up from 94 in Q2 2022.
- Funds reported $238M of Immunovant stock for Q3 2022, up 52% quarter-over-quarter.
- 23 funds opened new Immunovant positions in Q3 2022 and 5 closed out, a net change of +18 holders.
- The largest Immunovant buyer in Q3 2022 was Point72 Asset Management, an estimated $9.62M added.
- The largest Immunovant seller in Q3 2022 was Federated Hermes, an estimated $9.15M sold.
Based on aggregated 13F filings for Q3 2022.